Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

371.18USD
17 Feb 2017
Change (% chg)

$-1.84 (-0.49%)
Prev Close
$373.02
Open
$372.42
Day's High
$374.87
Day's Low
$370.00
Volume
278,181
Avg. Vol
316,770
52-wk High
$452.83
52-wk Low
$325.62

REGN.OQ

Chart for REGN.OQ

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $39,375.05
Shares Outstanding(Mil.): 106.08
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 48.14 47.80 29.39
EPS (TTM): 7.71 -- --
ROI: 17.01 -4.08 13.06
ROE: 22.10 4.84 14.19

Regeneron pins hope on eczema drug as Eylea sales slow

Regeneron Pharmaceuticals Inc Chief Executive Leonard Schleifer signaled that the U.S. biotech was on track to reduce its reliance on its flagship drug Eylea, as the company awaits the approval of two potential blockbuster treatments.

Feb 09 2017

UPDATE 3-Regeneron pins hope on eczema drug as Eylea sales slow

* Shares rise as much as 4 pct (Adds conference call details; updates shares)

Feb 09 2017

BRIEF-Regeneron says price increases unrelated from innovation will be pushed back on

* Regeneron CEO: "As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017"

Feb 09 2017

BRIEF-Regeneron posts Q4 adj. profit $3.04/shr

* Regeneron reports fourth quarter and full year 2016 financial and operating results

Feb 09 2017

Regeneron revenue rises 11.7 pct on Eylea eye drug

Feb 9 Regeneron Pharmaceuticals Inc reported an 11.7 percent rise in quarterly revenue on Thursday, helped by higher demand for its flagship eye drug Eylea.

Feb 09 2017

Regeneron, Sanofi win stay of U.S. order blocking cholesterol drug sales

A U.S. appeals court on Wednesday stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, while they appeal the order.

Feb 08 2017

Regeneron, Sanofi win stay of U.S. order blocking cholesterol drug sales

A U.S. appeals court on Wednesday stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, while they appeal the order.

Feb 08 2017

UPDATE 2-Regeneron, Sanofi win stay of U.S. order blocking cholesterol drug sales

Feb 8 A U.S. appeals court on Wednesday stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, while they appeal the order.

Feb 08 2017

BRIEF-Regeneron pharmaceuticals says appeals court grants stay of permanent injunction for praluent

* Regeneron Pharmaceuticals Inc says appeals court grants stay of permanent injunction for praluent (alirocumab) during appeals process

Feb 08 2017

Regeneron, Sanofi win stay of order blocking cholesterol drug sales

Feb 8 A U.S. appeals court on Wednesday has stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, later this month while they appeal.

Feb 08 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF77.00 +0.80
Pfizer Inc. (PFE.N) $33.62 0.00
Bayer AG (BAYGn.DE) €106.50 +0.55
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €81.49 -0.14
Merck & Co., Inc. (MRK.N) $65.39 +0.13
Amgen, Inc. (AMGN.OQ) $173.29 +1.18
Roche Holding Ltd. (ROG.S) CHF243.50 +0.70
Roche Holding Ltd. (RO.S) CHF246.30 +0.10
Eli Lilly and Co (LLY.N) $80.39 +0.35

Earnings vs. Estimates